Skip to main content Skip to main navigation menu Skip to site footer
Scientific Electronic Archives
Health Science
DOI: 10.36560/141120211450
Submitted: 2021-08-05
Published: 2021-10-29

Potential drug-drug interactions related with repurposed drugs for COVID-19

Universidade Federal de Mato Grosso - Campus Sinop
Universidade Federal de Mato Grosso - Campus Sinop
Universidade Federal de Mato Grosso - Campus Sinop
Universidade Federal de Mato Grosso - Campus Sinop
drug interactions. Covid-19. SARS-CoV-2. Coronavirus

Abstract

Since the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, existing molecules with some evidence in reducing the spread of the virus or to combat symptoms of this worldwide viral disease have been investigated. Drugs have been proposed to reduce viral load, virus entry into the host cell, inflammatory events, pulmonary edema or other signals and symptoms in patients with Covid-19. Two or more drugs are usually employed in therapies and a new circumstance, as Covid-19, increases the risk of more drugs to be prescribed for the patient. Thus, this work aimed to review the main drug interactions involving some repositioned drugs in Brazil for the treatment of Covid-19. We described moderate or severe risk interactions involving non-steroidal anti-inflammatory drugs, azithromycin, dexamethasone, dexchlorpheniramine, hydroxychloroquine, ivermectin and nitazoxanide. This review can support healthcare professionals at decisions about the pharmacotherapeutic strategies used in each patient with Covid-19.

Keywords: drug interactions. Covid-19. SARS-CoV-2. Coronavirus.

References

  1. HOSSEN, M.S. et al. A review on current repurposing drugs for the treatment of covid-19: reality and challenges [published online ahead of print, 2020 aug 31]. Sn compr clin med. 2020;1-13. Doi:10.1007/s42399-020-00485-9
  2. FACCENDA E, ARMSTRONG JF, DAVENPORT AP, HARDING SD, PAWSON AJ, SOUTHAN C & DAVIES JA. ([date retrieved]). Coronavirus information. Iuphar/bps guide to pharmacology. Retrieved from https://www.guidetopharmacology.org/coronavirus.jsp.
  3. ZHENG YY, Ma YT, ZHANG JY, XIE X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. Disponível em: https://www.nature.com/articles/s41569-020-0360-5?fbclid=IwAR3w4wcTno9A798v1fuYbALPLUHU5dNsVNVFKDc6GW-6yED2mXcyxrJY7dc.
  4. Hill M.A.; Mantzoros C, SOWERS, JR. Commentary: COVID-19 in patients with diabetes. Metabolism. 2020; 107:154217. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102643
  5. RECOVERY COLLABORATIVE GROUP, HORBY P, LIM WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report [published online ahead of print, 2020 Jul 17]. N Engl J Med. 2020; NEJMoa2021436. doi:10.1056/NEJMoa2021436.
  6. BIOT C, DAHER W, CHAVAIN N, ET AL. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J med chem. 2006;49(9):2845-2849. Doi:10.1021/jm0601856.
  7. LIU J, CAO R, XU M, ET AL. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting sars-cov-2 infection in vitro. Cell discov. 2020; 6:16. Published 2020 mar 18. Doi:10.1038/s41421-020-0156-0.
  8. MILLION M, LAGIER JC, GAUTRET P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020; 35:101738. doi:10.1016/j.tmaid.2020.101738.
  9. MEHRA MR, DESAI SS, RUSCHITZKA F, PATEL AN. RETRACTED: hydroxychloroquine or chloroquine with or without a macrolide for treatment of covid19: a multinational registry analysis [published online ahead of print, 2020 may 22] [retracted in: lancet. 2020 jun 5:null]. Lancet. 2020; s0140-6736(20)31180-6. doi:10.1016/S0140-6736(20)31180-6.
  10. SBFTE Sociedade Brasileira de Farmacologia e Terapêutica Experimental. Nota da SBFTE sobre a Covid-19. Disponível em: <https://www.sbfte.org.br/nota-sbfte-sobre-covid-19/>.
  11. SBFTE Sociedade Brasileira de Farmacologia e Terapêutica Experimental. Nota SBFTE sobre as orientações do Ministério da Saúde para manuseio medicamentoso de pacientes com diagnóstico da COVID-19. Disponível em: <https://www.sbfte.org.br/wp-content/uploads/2020/05/NOTA3_SBFTE_COVID.pdf>.
  12. NOËL, F. Imprecisões na posologia de cloroquina adotada e/ou reportada para o tratamento da covid-19: um alerta e uma lição. Disponível em: < https://www.sbfte.org.br/wp-content/uploads/2020/05/ASP_posologia_formas.pdf>.
  13. DRUGS.COM. KNOW MORE. BE SURE. Drugs interactions checker. Disponível em: < https://www.drugs.com/drug_interactions.html >.
  14. IBM MIICROMEDEX®. Drug interaction. Disponível em: <https://www.micromedexsolutions.com/micromedex2/librarian/pfdefaultactionid/evidencexpert.showdruginteractionsresults>.
  15. SIMPSON, T.F.; KOVACSE, R.J.; STECKER, E.C. Arritmias com as drogas usadas para pacientes com COVID-19. (2020). Disponível em: < https://www.cardiosite.com.br/arritmias-com-drogas-covid-19/ >.
  16. UNIVERSITY OF LIVERPOOL. Covid-19 drugs interactions. Disponível em: <https://www.covid19-druginteractions.org/checker>.
  17. ANVISA. Agência nacional de vigilância sanitária. Bulário eletrônico. 2007. Disponível em: <http://www.anvisa.gov.br/datavisa/fila_bula/frmvisualizarbula.asp >.
  18. CANGA, A.G. ET AL. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. Aaps j. v. 10, n. 1, p. 42-46. 2008. Doi: 10.1208/s12248-007-9000-9.
  19. ROCCO, P.R.M. et al. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. Eur Respir J, 2020; Disponível em: (https://doi.org/10.1183/13993003.03725-2020).

How to Cite

Silva, J. B. da, Rego, M. S., Santos, L. R. B. dos ., & Mueller, A. (2021). Potential drug-drug interactions related with repurposed drugs for COVID-19. Scientific Electronic Archives, 14(11). https://doi.org/10.36560/141120211450